Turn Therapeutics Inc (TTRX) FinancialsTTRXTurn Therapeutics Inc

Evaluating the bottom line, Turn Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -686.28%, provide a clear picture of how effectively TTRX converts its operational activities into shareholder value.

In the context of the broader market, TTRX competes directly with industry leaders such as EBS and AVIR. With a market capitalization of $337.39M, it holds a significant position in the sector. When comparing efficiency, TTRX's gross margin of N/A stands against EBS's 58.56% and AVIR's N/A. Such benchmarking helps identify whether Turn Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Turn Therapeutics has shown a year-to-date change of +119.19% and a one-year change of +106.84%, indicating strong price performance despite recent volatility.